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Background. Hypertension and dyslipidemia are independent risk factors for coronary heart disease and commonly coexist.
Cardiovascular risk can be reliably predicted using lipid ratios such as the atherogenic index, a useful prognostic parameter
for guiding timely interventions. Objective. We assessed the cardiovascular risk proile based on the atherogenic index of
residents within a rural Ugandan cohort. Methods. In 2011, a population based survey was conducted among 7507 participants.
Sociodemographic characteristics, physical measurements (blood pressure, weight, height, and waist and hip circumference), and
blood sampling for nonfasting lipid proile were collected for each participant. Atherogenic risk proile, deined as logarithm base
ten of (triglyceride divided by high density lipoprotein cholesterol), was categorised as low risk (<0.1), intermediate risk (0.1–0.24),
and high risk (>0.24). Results. Fity-ive percent of participants were female and the mean age was 49.9 years (SD±20.2). Forty-two
percent of participants had high and intermediate atherogenic risk. Persons with hypertension, untreated HIV infection, abnormal
glycaemia, and obesity and living in less urbanised villages were more at risk. Conclusion. A signiicant proportion of persons in
this rural population are at risk of atherosclerosis. Key identiied populations at risk should be considered for future intervention
against cardiovascular related morbidity and mortality. he study however used parameters from unfasted samples that may have
a bearing on observed results.
1. Background
Globally, cardiovascular disease (CVD) is the leading cause
of death with up to 80% occurring in low and middle income
countries (LMICs) [1]. Premature death due toCVD is rapidly
growing in Sub-Saharan Africa (SSA) [2]. Hypertension and
dyslipidemia are thought to be themajor risk factors for CVD
[3]. A systematic review on hypertension in SSA yielded 17
studies conducted between 1998 and 2008 in 11 countries and
found an overall prevalence of 16.2%, with small variation
between urban and rural communities [4]. In Uganda, the
prevalence of hypertension ranges from 14.6% in the rural
areas [5] to 27.2% in the periurban area [6]. In Western pop-
ulations, dyslipidemia among patients with hypertension is a
common inding. he prevalence of dyslipidemia coexisting
with hypertension has been estimated at 15–24% [3, 7]. Over
40% of all newly diagnosed hypertensive patients have at
least one lipid abnormality [8]. here is dearth of data on the
burden of dyslipidemia among patients with hypertension in
SSA.
Hypertension and dyslipidemia are both independent
modiiable risk factors for CVD. However, some studies
suggest that dyslipidemia may play a role in the development
of hypertension via endothelial damage [9]. he risk for
CVD is higher in the presence of both hypertension and
dyslipidemia than by the individual disease entities [10]. In
high income countries, strategies targeting the reduction of
serum cholesterol levels provide the single most important
beneit against CVD resulting from coronary heart disease
(CHD) when evaluated in a cohort setting [11]. A review on
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a number of cohort studies and randomised clinical trials
found that a 10% decrease in cholesterol reduced the risk of
CHD by 50% at the age of 40 and this beneit reduces to
20% by the age of 70 [12]. In contrast, blood pressure control
provides only a 20% risk reduction of mortality due to CHD
in high income settings.
Current medical practice encourages risk stratiication
for all persons at risk of CHD including those with hyperten-
sion.his is advantageous for timely intervention in prevent-
ing CHD and its sequelae. Cardiovascular risk assessment
based solely on serum low density lipoprotein cholesterol
(LDL-C) has been found to be inadequate [13, 14] and even
in persons on statin therapy with normal or near normal
LDL-C serum levels, there remains risk for future cardiovas-
cular events. Hypertriglyceridemia has been identiied as an
independent cardiovascular risk factor [15, 16]. Hypertriglyc-
eridemia is a proxy for atherogenic dyslipidemia (elevatedTG
(triglyceride) and low high density lipoprotein cholesterol)
[16, 17], a component of themetabolic syndrome and a known
risk factor for CHD. Despite interaction with other lipids
that might increase atherogenic risk and in-subject variation,
elevated TG has been shown to be a good predictor of CHD
in consideration of the high density lipoprotein cholesterol
(HDL-C) levels [17] and is used in clinical practice to predict
atherosclerosis [17, 18]. he lipid ratio log [TG/HDL-C]
(atherogenic index) provides an alternative simple option
for risk stratiication. he use of this ratio is to relect the
balance between risk and protective lipoprotein forces [15]
as well as acting as a correlate with LDL-C particle size [19],
LDL-phenotype B, and small HDL-C particles [16].his ratio
has also been evaluated as a prognostic tool in predicting
CHD [16] and its predictive value far outweighs that of
absolute lipid parameters [20, 21] as well as the TC (total
cholesterol)/HDL ratio [21] given its strong correlation with
lipoprotein particle size.
Uganda bears a signiicant burden of hypertension [22]
and like other SSA countries is not presently equipped with
the necessary resources, expertise, and technology tomanage
the CVD sequelae. A recent study done within a rural
population relected the dominant dyslipidemic pattern to be
that of low serum HDL-C levels and a good proportion with
hypertriglyceridemia [23].Whereas there arewell-recognised
recommendations on the use of serum LDL-C and TC for
cardiovascular risk assessment, there is limited progress in
addressing concerns with low serumHDL-C which may lead
to underestimation of CHD risk [24]. he atherogenic index
provides a simple and reliable method for point of care risk
assessment that can be done by nonspecialists even within
hard-to-reach areas. he aim of this study was to assess the
atherogenic risk proile using the atherogenic index among
people living in rural Uganda.
2. Methods
2.1. Design and Setting. A population based survey was
conducted in 2011 among 7507 individuals aged 13 years and
above living in an established rural cohort in southwestern
Uganda, the General Population Cohort (GPC) consisting
of 25 villages. his cohort has been in existence for the last
25 years and was initially established for the purpose of
investigating HIV trends in rural Uganda. Research activities
have since been broadened to include noncommunicable
diseases, assessing burden and risk factors [25].
2.2. Study Procedures
2.2.1. Questionnaire. Sociodemographic information was
collected for each participant and entered into an electronic
questionnaire. his information included age, sex, and occu-
pation, level of education, marital status, smoking history,
and use of alcohol. he level of urbanicity was determined
and presented as described elsewhere [26].
2.2.2. Physical Measurements. Blood pressure measurement,
height, weight, and hip and waist circumferences were mea-
sured as described by Riha et al. 2014 [26]. Participants found
to have systolic blood pressure ≥140mmHg and/or diastolic
pressure ≥90mmHgwere referred to as having hypertension.
Participant categorisation using body mass index (BMI)
was as follows: BMI ≤ 18.5, “underweight,” BMI 18.5–24.9,
“normal weight,” BMI 25–29.9, “overweight,” and BMI ≥ 30,
“obese”. Categorisation by waist-hip ratio (WHR) was as
follows: abnormal in male if >0.95 and abnormal in females
if >0.8.
2.2.3. Laboratory Measurements. Participants underwent
phlebotomy for purposes of a nonfasting lipid proile (TC,
TG, HDL-C, and low density lipoprotein cholesterol (LDL-
C)), HIV serology, and glycated haemoglobin (HbA1c). All
blood samples were transported on the same day to a
central laboratory for sample processing and testing. Lipid
proile analysis was done using the enzymatic colorimetric
assay by the Cobas Integra 400 Plus. Cut-of values for
the diferent lipid parameters representative of dyslipidemia
were as follows: TC > 5.2mmol/L, TG > 2.3mmol/L, LDL-
C > 3.4mmol/L, and HDL-C < 1.04mmol/L, male, and
<1.3mmol/L, female. Participants with HbA1c ≥ 6.5% were
termed as diabetic, HbA1c 6–6.49% were termed as high risk
for diabetes, and HbA1c < 6% were termed as low risk for
diabetes [27]. HIV testing was done in accordance with the
Ministry of Health guidelines [28].
2.3. Data Analysis. To assess the atherogenic risk we used the
atherogenic index deined as log(triglycerides/HDL-C). he
risk was categorised into low (<0.1), intermediate (0.1–0.24),
and high (>0.24) [21].
he sample was described using proportions by sex. Age
and systolic and diastolic blood pressure were summarized
with means and corresponding standard deviations (SD).
Atherogenic risk was determined using proportions in each
category and the chi-squared test was used to compare
proportions. We used the ordered logistic regression model
to evaluate the efect of demographic characteristics, blood
pressure, lipid proiles, and HIV status on atherogenic risk
and the results were presented by sex. To avoid residual
confounding and loss of power, continuous lipid mea-
sures were modelled as continuous rather than categorised.
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he continuous variables were included into the model as
centered and assessed for nonlinearity by itting a irst-
order fractional polynomial to the data. he proportional
odds assumption in using the ordered logistic regression
was tested. Analysis was done using STATA 13 (Stata Corp,
College Station, TX).
2.4. Ethical Consideration. hestudywas conducted in accor-
dance with the principles of the Declaration of Helsinki
and was approved by the Uganda Virus Research Insti-
tute Research Ethics Committee (UVRI REC) in Entebbe,
Uganda, and by the Uganda National Council of Science
and Technology (UNSCT). Written informed consent was
obtained from all study participants. For participants below
the age of 18 years, parental consent and formal assent to
participate in the study were obtained as per the Ugan-
dan National Guidelines for Research Involving Humans as
Research Participants [29]. Participants with hypertension
and raised serum lipids were referred to a care clinic for
further management and received standard of care (health
education on risk factor prevention and/or control and drug
therapy with statins).
3. Results
3.1. Baseline Characteristics. he study enrolled 7507 partic-
ipants, the majority were females (55%), and the mean age
was 49.9 years (SD ± 20.2). here were equal distributions
of participants across the diferent levels of urbanicity, most
of the participants were under the age of 30, and the use
of alcohol and tobacco was more common among the male
participants (Table 1).
From the physical and laboratory measurements we
found more female participants to be overweight and obese
and have an abnormal WHR. Approximately 18% of partici-
pants were identiied as having hypertension and only 2%had
controlled hypertension on treatment. he most common
form of dyslipidemia was low serum HDL-C levels (Table 1).
3.2. Atherogenic Risk. he proportion of participants with
intermediate and high atherogenic risk was 17% and 25%,
respectively, with the greater proportion at high risk being
male participants (Figure 1).
3.3. Risk Factors for High Atherogenic Risk. Participants with
hypertension (particularly those with suboptimal control
on treatment), residents from less urbanised villages, HIV-
infected participants not on antiretroviral therapy (ART),
overweight and obese participants, and participants with
abnormalHbA1c had signiicantly higher odds of having high
atherogenic risk (Table 2).
Being female, 30 years of age and above, having attained
higher level of education, current consumption of alcohol,
and being on ART were signiicantly associated with lower
odds of having high atherogenic risk. Abnormal total choles-
terol serum levels and history of smoking had no association
with atherogenic risk.
All participants (%) Male (%) Female (%)
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Figure 1: Atherogenic risk proile among study participants strati-
ied by gender.
4. Discussion
With increasing globalisation, varying degrees of urbanisa-
tion exist even within rural areas [26]. Urbanisation inlu-
ences environmental and individual factors that may have
impact on cardiovascular risk. In this study we assessed the
risk for atherosclerosis using the atherogenic index in a rural
Ugandan cohort. he atherogenic index in comparison to
absolute lipid parameters and to TC/HDL-C ratio provides
more accurate estimates of cardiovascular risk [30] and is
more likely to be a better screening tool. Our study is one
of the few studies in the region that provides insight into the
use of the atherogenic index and having a cohort already in
establishment provides the unique opportunity to conduct
pilot studies that generate hypotheses to guide future research
in this ield.his study also assesses the use of the atherogenic
index in a widely distributed rural population and is not only
restricted to most at-risk populations. he atherogenic index
requires minimal expertise and can be widely implemented
as a screen method for cardiovascular disease even within
remote locations.
A signiicant proportion of participants were at risk of
atherosclerosis. A population based survey done in Iran and
using the atherogenic index found a similar high estimate of
atherogenic risk [31]. he INTERHEART study, an observa-
tional study involving 52 countries spread across all conti-
nents, found that persons with history of myocardial infarc-
tion had three times the odds of having a raised ApoB/ApoA1
ratio (surrogate for atherogenic dyslipidemia) compared to
persons without history of myocardial infarction [32]. An
observational study done in Brazil found that persons with
coronary disease had two times the odds of having an
abnormal TG/HDL-C ratio [33]. In our study participants
with hypertension had higher odds of risk for atherosclerosis.
We found that 27% of participants with hypertension had
a high atherogenic risk, a higher estimate compared to a
Nigerian study that found a lower proportion of patients with
hypertension at risk for CHD using LDL-C/HDL-C ratios
for risk stratiication [30]. We attributed this diference in
proportions to the atherogenic index being a correlate to
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Table 1: Sociodemographic, clinical, physical, and biochemical characteristics of cohort by gender.
All participants Sex
� (%) Male, � (%) Female, � (%)
All 7507 3378 4129
Demographic characteristics
Age, in years
13–29 3679 (49.0) 1804 (53.4) 1875 (45.4)
30–59 2978 (39.7) 1226 (36.3) 1752 (42.4)
60+ 850 (11.3) 348 (10.3) 502 (12.2)
Urbanicity score∗
Quartile 1 (least urban) 1978 (26.4) 884 (26.2) 1094 (26.5)
Quartile 2 1893 (25.2) 848 (25.1) 1045 (25.3)
Quartile 3 1946 (25.9) 888 (26.3) 1058 (25.6)
Quartile 4 (most urban) 1690 (22.5) 758 (22.4) 932 (22.6)
Highest education level
None/up to P4 2112 (28.1) 876 (25.9) 1236 (29.9)
P5–P7 3365 (44.8) 1579 (46.7) 1786 (43.3)
Secondary+ 2030 (27.0) 923 (27.3) 1107 (26.8)
Occupation
Subsistence crop 2975 (39.6) 1102 (32.6) 1873 (45.4)
Cash crop cultivator 934 (12.4) 491 (14.5) 443 (10.7)
Noncrop 1043 (13.9) 625 (18.5) 418 (10.1)
Unemployed/full-time education 2555 (34.0) 1160 (34.3) 1395 (33.8)
Marital status∗∗
Not married/divorced 3861 (51.5) 1842 (54.6) 2019 (48.9)
Married/living 3638 (48.5) 1532 (45.4) 2106 (51.1)
Lifestyle characteristics
Smoking
Never smoked 6747 (89.9) 2707 (80.1) 4040 (97.8)
Ever smoked daily 760 (10.1) 671 (19.9) 89 (2.2)
Alcohol consumption
Never drinker 4844 (64.5) 2032 (60.2) 2812 (68.1)
Ex-drinker 583 (7.8) 235 (7.0) 348 (8.4)
Current drinker 2080 (27.7) 1111 (32.9) 969 (23.5)
Biophysical characteristics
BMI group
Underweight (<18.5) 1701 (22.7) 1022 (30.3) 679 (16.4)
Normal (18.5–24.9) 4878 (65.0) 2179 (64.5) 2699 (65.4)
Overweight (≥25) 730 (9.7) 156 (4.6) 574 (13.9)
Obese 198 (2.6) 21 (0.6) 177 (4.3)
Waist-hip ratio (WHR)
Normal (≤0.95-m, ≤0.80-f) 4440 (59.1) 3257 (96.4) 1183 (28.7)
Abnormal (>0.95-m, >0.80-f) 3067 (40.9) 121 (3.6) 2946 (71.3)
Biochemical characteristics
Total cholesterol
Desirable (≤5.2mmol/L) 7084 (94.4) 3270 (96.8) 3814 (92.4)
High (>5.2mmol/L) 423 (5.6) 108 (3.2) 315 (7.6)
Triglycerides
Desirable (≤2.3mmol/L) 7190 (95.8) 3261 (96.5) 3929 (95.2)
High (>2.3mmol/L) 317 (4.2) 117 (3.5) 200 (4.8)
LDL-C
Desirable (≤3.4mmol/L) 7134 (95.0) 3286 (97.3) 3848 (93.2)
High (>3.4mmol/L) 373 (5.0) 92 (2.7) 281 (6.8)
HDL-C
Desirable (≥1.04-m, 1.3-f) 1940 (25.8) 1127 (33.4) 813 (19.7)
Undesirable (<1.04-m, 1.3-f), low 5567 (74.2) 2251 (66.6) 3316 (80.3)
HbA1-C
Normal (≤6%) 7469 (99.7) 3359 (99.8) 4110 (99.7)
Raised (≥6.5%) 19 (0.3) 7 (0.2) 12 (0.3)
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Table 1: Continued.
All participants Sex
� (%) Male, � (%) Female, � (%)
Clinical characteristics
Hypertension status
Normal BP 6163 (82.1) 2799 (82.9) 3364 (81.5)
Normal BP on treatment 173 (2.3) 56 (1.7) 117 (2.8)
Raised on treatment 119 (1.6) 31 (0.9) 88 (2.1)
Raised BP, not on treatment 1050 (14.0) 492 (14.6) 558 (13.5)
HIV/ART status
Negative 6821 (92.0) 3103 (93.5) 3718 (90.7)
Positive, on ART 201 (2.7) 63 (1.9) 138 (3.4)
Positive, not on ART 396 (5.3) 152 (4.6) 244 (6.0)
Atherogenic risk
Low (<0.1) 4341 (57.8) 1878 (55.6) 2463 (59.7)
Intermediate (0.1–0.24) 1259 (16.8) 583 (17.3) 676 (16.4)
High (>0.24) 1907 (25.4) 917 (27.1) 990 (24.0)
∗Riha et al. 2014 [26].
∗∗8 missing pieces of information.
lipoprotein size [21] which may predict risk better. Partici-
pants on treatment, but with uncontrolled hypertension, were
more likely to be at risk of atherosclerosis compared to those
not on treatment and those with controlled hypertension.
Literature shows that blood pressure control gives minimal
reduction of cardiovascular risk especially among those older
than 40 years [12] and in our study we found the mean age to
be 49 years. his could explain why even among participants
on treatment and controlled hypertension atherogenic risk
was still high. Participants that were HIV infected and ART
naive were more likely to have a high atherogenic risk, a
inding similar to other studies done, possibly owing to their
high inlammatory state [34]. he use of ART was found
to be protective as ART is thought to reduce inlammatory
markers and provide cardioprotection [35]. However, other
studies have found the use of protease inhibitors (PI) to
increase the serum levels of atherogenic lipoproteins [34]. In
this population irst-line therapy was non-PI based and could
further explain our indings. We also observed that a high
atherogenic index was less prevalent in participants aged 60
years and above and yet it is more likely that individuals in
this age category are more at risk of cardiovascular events.
he HIV prevalence in this cohort is higher in the younger
age group and we thought this may be the main driver for the
increased risk in this age group.
Abnormal HbA1c as a screen for diabetes was also found
to be associated with high atherogenic risk. Diabetes afects
the integrity of the vasculature and is also associated with
other conditions that predispose to CHD, such as hyperten-
sion and dyslipidemia that may explain the increased risk.
Previous epidemiological studies have shown cholesterol to
predict risk of CHD and LDL-C to be associated with future
risk [36]; however, we did not ind any association between
high serum cholesterol levels and atherogenic risk in this
rural population. Similar to the Framingham study [36] and
the INTERHEART study [32] we demonstrated that obesity
and abdominal obesity were associated with increased risk
of CHD in this study population. Our study showed that
participants from less urbanised villages were more likely
to be at high risk for CHD. However previous studies done
within this same population showed that persons in less
urbanised villages were more likely to indulge in physical
activity and eat fruits and vegetables [26], factors thought to
reduce risk for CHD. It may be possible that a diferent set of
risk factors, yet to be explored, is responsible for the risk of
CHD in this population.
Our study was limited in that we did not derive lipid
parameters from fasted samples which may impact on risk
estimation if there should be any variation with parameters
derived ater fasting. We also did not ascertain diferences
among the subcategories of participants with hypertension
that may have accounted for diferences in risk proile. he
design of the study did not allow making inferences as to
casualty. However this study provides insight into estimated
cardiovascular risk in a widely distributed rural population
taking into account environmental, infectious, and noninfec-
tious risk factors and provides a platform for further research
into possible causes of high atherogenic risk whose indings
may give information on preventive strategies.
5. Conclusion
A signiicant proportion of persons in this rural Ugandan
population are at risk of atherosclerosis. Persons with hyper-
tension, untreated HIV infection, abnormal glycaemia, and
obesity appear to be more at risk and may be considered as
target groups for intervention programs. Follow-up studies
are needed to further assess other risk factors including the
role of genetics in cardiovascular risk in this population.
6 Journal of Tropical Medicine
Table 2: Factors associated with high atherogenic risk.
Covariates
High atherogenic risk
Crude OR�
Adjusted OR�
Overall � value
� (%) b/ci95
Hypertension status
Normal BP (≤140/90mmHg) (� = 6163) 1538 (25.0) 1 0.022 1 0.007
Normal BP on treatment (� = 173) 53 (30.6) 1.34 (1.01–1.78) 1.32 (0.98–1.79)
Raised BP (≥140/90mmHg) on treatment (� = 119) 36 (30.3) 1.51 (1.08–2.11) 1.53 (1.07–2.18)
Raised BP not on treatment (� = 1050) 280 (26.7) 1.04 (0.91–1.18) 1.17 (1.00–1.37)
Sex
Male (� = 3378) 917 (27.1) 1 <0.001 1 <0.001
Female (� = 4129) 990 (24.0) 0.85 (0.77–0.93) 0.57 (0.50–0.66)
Age, in years
13–29 (� = 3679) 980 (26.6) 1 0.001 1 <0.001
30–59 (� = 2978) 727 (24.4) 0.88 (0.80–0.97) 0.84 (0.75–0.94)
60+ (� = 850) 200 (23.5) 0.84 (0.71–1.00) 0.71 (0.58–0.87)
Urbanicity score
Quartile 1 (least urban) (� = 1978) 488 (24.7) 1 <0.001 1 0.018
Quartile 2 (� = 1893) 535 (28.3) 1.15 (1.02–1.30) 1.16 (1.02–1.31)
Quartile 3 (� = 1946) 473 (24.3) 0.94 (0.83–1.07) 0.96 (0.85–1.09)
Quartile 4 (very urban) (� = 1690) 411 (24.3) 0.95 (0.83–1.10) 0.98 (0.86–1.12)
Highest education level
None/up to p4 (� = 2112) 596 (28.2) 1 <0.001 1 <0.001
P5–P7 (� = 3365) 880 (26.2) 0.85 (0.77–0.95) 0.81 (0.73–0.91)
Secondary+ (� = 2030) 431 (21.2) 0.66 (0.58–0.76) 0.64 (0.55–0.74)
Cigarette consumption
Never smokers (� = 6747) 1718 (25.5) 1 0.992 1 0.471
Ever smokers (� = 760) 189 (24.9) 1.00 (0.86–1.16) 0.94 (0.79–1.11)
Alcohol consumption
Never drinkers (� = 4844) 1276 (26.3) 1 <0.001 1 <0.001
Ex-drinkers (� = 583) 155 (26.6) 1.06 (0.90–1.25) 1.00 (0.84–1.20)
Current drinkers (� = 2080) 476 (22.9) 0.81 (0.73–0.89) 0.78 (0.69–0.88)
HIV/ART status
Negative (� = 6821) 1711 (25.1) 1 <0.001 1 <0.001
Positive, on ART (� = 201) 33 (16.4) 0.54 (0.39–0.73) 0.57 (0.41–0.78)
Positive, not on ART (� = 396) 133 (33.6) 1.62 (1.34–1.96) 1.76 (1.45–2.13)
BMI category
Underweight (� = 1701) 459 (27.0) 1 <0.001 1 <0.001
Normal (� = 4878) 1177 (24.1) 0.85 (0.76–0.95) 0.98 (0.87–1.10)
Overweight (� = 730) 197 (27.0) 1.07 (0.91–1.27) 1.29 (1.07–1.55)
Obese (� = 198) 74 (37.4) 1.70 (1.29–2.24) 2.08 (1.55–2.79)
Waist-hip ratio
Normal, ≤0.95-m, ≤0.80-f (� = 4440) 1065 (24.0) 1 0.001 1 <0.001
Abnormal, >0.95-m, >0.80-f (� = 3067) 842 (27.5) 1.17 (1.07–1.28) 1.55 (1.36–1.77)
Total cholesterol (mmol/L)
Desirable (≤5.2) (� = 7084) 1814 (25.6) 1 0.291 1 0.359
High (>5.2) (� = 423) 93 (22.0) 0.90 (0.74–1.09) 0.91 (0.74–1.12)
HbA1-C
Normal ≤6% (� = 7469) 1891 (25.3) 1 0.004 1 0.014
Raised ≥6.5% (� = 19) 11 (57.9) 3.65 (1.49–8.93) 3.17 (1.27–7.96)
�High atherogenic risk versus intermediate and low risk.
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